Vitamin D receptor presence in breast cancer tumors linked to better survival outcomes

In a recent study published in the journal Nutrients, researchers explored the role of vitamin D receptors (VDR) as a potential prognostic marker for breast cancer.

Their results indicate significant associations between VDR, the mode of detection, and the size of invasive tumors, suggesting a promising avenue for further study.

Study: The Vitamin D Receptor as a Prognostic Marker in Breast Cancer—A Cohort Study. Image Credit: Peddalanka Ramesh Babu / ShutterstockStudy: The Vitamin D Receptor as a Prognostic Marker in Breast Cancer—A Cohort Study. Image Credit: Peddalanka Ramesh Babu / Shutterstock

Background

People with breast cancer often show lower serum levels of vitamin D compared to healthy individuals; some studies have also found links between low vitamin D levels and the probability of an adverse prognosis, while others suggest that supplementation could reduce the risk of developing advanced cancer.

Calcitriol, an active metabolite of vitamin D, binds to the VDR before it translocates into the nucleus, modifying regulatory genes that control cell signaling, apoptosis, and cell growth.

This could be a mechanism that underlies the association between VDR and favorable breast cancer prognoses, but further research is needed to understand its potential role as a biomarker for the progression of tumors.

About the study

In this study, researchers attempted to validate prior work that found positive associations between breast cancer prognoses and nuclear VDR presence. They additionally explored if prognostic information can be refined by VDR subcellular localization.

The dataset included tumor samples obtained from individuals who received a diagnosis of primary breast cancer between October 2002 and June 2012. The samples were utilized for tissue microarray (TMA) construction after excluding people who had received a prior diagnosis of any cancer in the previous 10 years.

During preoperative visits, patients were asked to complete questionnaires that included information on reproductive factors, lifestyles, and medication and supplements consumed during the previous week. Vitamin D consumption was calculated from the product information for supplements.

Nurses measured hip and waist circumference, height, weight, and breast volume. Pathology reports were used to obtain characteristics of tumors, including size, histologic type, grade, involvement of axillary lymph nodes, and status of progesterone receptors (PR) and estrogen receptors (ER).

Pathological assessment of human epidermal growth factor receptor 2 (HER2) status and TMA were assessed jointly using microscopic methods after blinding. In multiple subcellular locations of invasive tumor cells, VDR staining was examined in the nuclear membrane (VDRnum), cytoplasm (VDRcyt), and nucleus (VDRnuc).

During the final follow-up in 2019, medical records, pathology reports, and national registries for population and tumors were used to calculate the breast cancer-free interval (BCFI) and calculate endpoints (death or last follow-up) for survival analyses.

Findings

On average, patients were 61 years old, and VDR was obtained for 878 tumors; cytoplasmic intensity evaluations showed that 7% were VDR-negative, while VDRnum was positive in 25% of patients. Tumors included in the analysis were, on average, large, of a higher grade, and more likely to be lymph node-negative than those that were excluded.

Microscopic representative images of immunohistochemical staining intensities of nuclear membrane and cytoplasmic VDR (40×) in the TMA. Bar represents 20 µm.Microscopic representative images of immunohistochemical staining intensities of nuclear membrane and cytoplasmic VDR (40×) in the TMA. Bar represents 20 µm.

Patients with VDRnum-positive tumors had smaller waist circumferences and breast volumes on average and were more likely to have screening-detected tumors. VDRnum-positive tumors were linked with lower tumor grade, positive hormone receptors, and the absence of HER2 amplification.

After surgery, more VDRnum-negative patients received chemotherapy and trastuzumab, while VDRnum-positive patients received further endocrine therapy. In terms of prognosis, patients with VDRnum-positive tumors had better outcomes in both BCFI and overall survival (OS) in univariable analysis. This effect persisted after adjusting for various factors.

When VDR localization was considered, VDRnum-positive tumors showed the best prognosis regardless of VDRcyt. Patients with both ER-positive and VDRnum-positive tumors had the best prognosis, while those with ER-negative and VDRnum-negative tumors had the worst. Even among ER-positive tumors, VDRnum-positive tumors were associated with lower tumor grade and longer OS.

Interaction analyses suggested that VDRnum interacts with the mode of detection and size of tumors in the case of BCFI. Larger VDRnum-positive tumors (>20 mm) were associated with significantly fewer breast cancer events than small ones. Clinically detected VDRnum-positive tumors showed better BCFI than screening-detected ones.

Conclusions

This study highlights significant correlations between positive VDR staining in the nuclear membranes of breast cancer cells and favorable characteristics of tumors, OS, and longer BCFI.

Results indicate that evaluating nuclear membrane VDR levels may be a better prognosis predictor compared to cytoplasmic levels. VDRnum status could refine luminal breast cancer selection with favorable prognoses, especially when considering interactions with tumor size and detection mode.

VDR expression inversely correlates with aggressiveness, particularly in triple-negative and HER2-amplified cancers, possibly due to mutations in the tumor protein p53. Further research is needed to standardize VDR evaluation methods and explore associations with vitamin D levels.

The study suggests potential clinical relevance for VDR as a prognostic marker and underscores the need for understanding the interplay between vitamin D, VDR, and breast cancer outcomes. Since most participants in the study were of European descent, heterogeneous populations should be included in future studies to ensure the generalizability of findings.

Journal reference:
  • The vitamin D receptor as a prognostic marker in breast cancer – a cohort study. Huss, L., Gulz-Haake, I., Nilsson, E., Tryggvadottir, H., Nilsson, L., Nodin, B., Jirström, K., Isaksson, K., Jernström, H. Nutrients (2024). 10.3390/nu16070931, https://www.mdpi.com/2072-6643/16/7/931
Priyanjana Pramanik

Written by

Priyanjana Pramanik

Priyanjana Pramanik is a writer based in Kolkata, India, with an academic background in Wildlife Biology and economics. She has experience in teaching, science writing, and mangrove ecology. Priyanjana holds Masters in Wildlife Biology and Conservation (National Centre of Biological Sciences, 2022) and Economics (Tufts University, 2018). In between master's degrees, she was a researcher in the field of public health policy, focusing on improving maternal and child health outcomes in South Asia. She is passionate about science communication and enabling biodiversity to thrive alongside people. The fieldwork for her second master's was in the mangrove forests of Eastern India, where she studied the complex relationships between humans, mangrove fauna, and seedling growth.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Pramanik, Priyanjana. (2024, March 25). Vitamin D receptor presence in breast cancer tumors linked to better survival outcomes. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/news/20240325/Vitamin-D-receptor-presence-in-breast-cancer-tumors-linked-to-better-survival-outcomes.aspx.

  • MLA

    Pramanik, Priyanjana. "Vitamin D receptor presence in breast cancer tumors linked to better survival outcomes". News-Medical. 31 October 2024. <https://www.news-medical.net/news/20240325/Vitamin-D-receptor-presence-in-breast-cancer-tumors-linked-to-better-survival-outcomes.aspx>.

  • Chicago

    Pramanik, Priyanjana. "Vitamin D receptor presence in breast cancer tumors linked to better survival outcomes". News-Medical. https://www.news-medical.net/news/20240325/Vitamin-D-receptor-presence-in-breast-cancer-tumors-linked-to-better-survival-outcomes.aspx. (accessed October 31, 2024).

  • Harvard

    Pramanik, Priyanjana. 2024. Vitamin D receptor presence in breast cancer tumors linked to better survival outcomes. News-Medical, viewed 31 October 2024, https://www.news-medical.net/news/20240325/Vitamin-D-receptor-presence-in-breast-cancer-tumors-linked-to-better-survival-outcomes.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Low vitamin D associated with increased depression risk in pregnancy and after birth